|
|
|
Volumn 5, Issue 1, 2005, Pages 425-435
|
|
The challenge of assuring continued post-trial access to beneficial treatment.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
NEW DRUG;
ARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
CLINICAL TRIAL;
ETHICS;
HEALTH;
HEALTH CARE AND PUBLIC HEALTH;
HEALTH CARE DELIVERY;
HEALTH CARE QUALITY;
HUMAN;
HUMAN EXPERIMENT;
INTERNATIONAL COOPERATION;
MORALITY;
PATIENT CARE;
PRACTICE GUIDELINE;
RESEARCH ETHICS;
UNITED STATES;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
HEALTH CARE AND PUBLIC HEALTH;
ANTI-HIV AGENTS;
CLINICAL TRIALS;
CONTINUITY OF PATIENT CARE;
DRUGS, INVESTIGATIONAL;
ETHICS, RESEARCH;
GUIDELINES;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
INTERNATIONAL AGENCIES;
INTERNATIONAL COOPERATION;
MORAL OBLIGATIONS;
QUALITY ASSURANCE, HEALTH CARE;
THERAPEUTIC HUMAN EXPERIMENTATION;
UNITED STATES;
WORLD HEALTH;
|
|
EID: 14644413526
PISSN: 15353532
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (51)
|
|
References (0)
|
